An anti-aging composition

Abstract

The present application relates to an anti-aging composition. Specifically, the present application provides a composition comprising a Paris extract and / or a Panax notoginseng extract. The Paris extract and the Panax notoginseng extract of the present application have excellent anti-aging effects, and the Paris extract and the Panax notoginseng extract have a synergistic effect in terms of anti-aging.

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical technology, specifically to an anti-aging composition. Background Technology

[0002] Skin aging is a common phenomenon, caused by many factors such as ultraviolet radiation. Aging skin often has a decreased collagen content. Collagen, such as type III collagen, secreted by skin fibroblasts plays a supporting and structural role in the skin, maintaining its elasticity and firmness. The reduction of collagen leads to sagging skin and wrinkles. Supplementing collagen can help maintain skin elasticity and firmness, thereby slowing down the aging process and achieving cosmetic skincare effects. However, current technology lacks effective anti-aging products and methods. With the continuous improvement of living standards and health requirements, developing anti-aging products and methods has become a current research hotspot.

[0003] Therefore, there is a need in this field to develop an anti-aging product and method. Summary of the Invention

[0004] The purpose of this invention is to provide a composition for anti-aging.

[0005] A first aspect of the present invention provides a composition comprising Paris polyphylla extract and / or Panax notoginseng extract.

[0006] Preferably, the composition comprises Paris polyphylla extract and Panax notoginseng extract.

[0007] Preferably, the extract is a dry extract.

[0008] Preferably, the extract is a dry extract.

[0009] Preferably, the weight ratio of the Paris polyphylla extract to the Panax notoginseng extract is 1:5-200, more preferably 1:5-100, even more preferably 1:10-90, even more preferably 1:10-80, even more preferably 1:10-70, even more preferably 1:20-60, even more preferably 1:25-55, even more preferably 1:30-50, even more preferably 1:35-45, even more preferably 1:38-42, and even more preferably 1:40.

[0010] Preferably, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0011] (1) Extract Paris polyphylla with an aqueous ethanol solution to obtain an extract. The extract is then extracted with petroleum ether, and the separated aqueous layer is extracted with ethyl acetate. The separated aqueous layer is then extracted with n-butanol to obtain an n-butanol layer extract. The n-butanol layer extract is then evaporated to dryness to obtain Paris polyphylla extract.

[0012] Preferably, in step (1), the volume fraction of ethanol in the aqueous ethanol solution is 30-90%, more preferably 50-90%, more preferably 60-80%, more preferably 65-75%, more preferably 68-72%, and most preferably 70%.

[0013] Preferably, in step (1), the ethanol-water solution is extracted by heating and reflux extraction.

[0014] Preferably, in step (1), Paris polyphylla is extracted with an ethanol aqueous solution and then filtered to obtain an extract.

[0015] Preferably, in step (1), the extraction time of Paris polyphylla by the ethanol aqueous solution is 0.5-5h, more preferably 1-3h, more preferably 1-2h, more preferably 1.3-1.7h, and most preferably 1.5h.

[0016] Preferably, in step (1), the weight ratio of the Paris polyphylla raw material to the ethanol aqueous solution is 1:3-12, more preferably 1:3-10, even more preferably 1:4-8, more preferably 1:5-7, more preferably 1:5.5-6.5, and most preferably 1:6.

[0017] Preferably, in step (1), the extract is concentrated and then extracted with petroleum ether.

[0018] Preferably, the concentration method includes vacuum concentration.

[0019] Preferably, the concentration factor is 3-10 times, more preferably 4-8 times, even more preferably 5-7 times, even more preferably 5.5-6.5 times, and most preferably 6 times.

[0020] Preferably, in step (1), the volume ratio of the concentrated extract to the aqueous ethanol solution is 1:3-12, more preferably 1:3-10, even more preferably 1:4-8, more preferably 1:5-7, more preferably 1:5.5-6.5, and most preferably 1:6.

[0021] Preferably, in step (1), the volume ratio of petroleum ether to the extract is (0.5-1.5):(0.5-1.5), more preferably (0.8-1.2):(0.8-1.2), and most preferably 1:1.

[0022] Preferably, in step (1), the volume ratio of the petroleum ether to the concentrated extract is (0.5-1.5):(0.5-1.5), more preferably (0.8-1.2):(0.8-1.2), and most preferably 1:1.

[0023] Preferably, in step (1), the volume ratio of ethyl acetate to the aqueous layer separated by petroleum ether extraction is (0.5-1.5):(0.5-1.5), more preferably (0.8-1.2):(0.8-1.2), and most preferably 1:1.

[0024] Preferably, in step (1), the volume ratio of n-butanol to the aqueous layer separated by ethyl acetate extraction is (0.5-1.5):(0.5-1.5), more preferably (0.8-1.2):(0.8-1.2), and most preferably 1:1.

[0025] Preferably, the evaporation is performed by vacuum concentration evaporation.

[0026] Preferably, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0027] (1) Add Paris polyphylla to a 65-75% (v / v) ethanol aqueous solution, heat and reflux to extract, and then add petroleum ether to the extract for extraction. The separated aqueous layer is extracted with ethyl acetate, and then the separated aqueous layer is extracted with n-butanol to obtain the n-butanol layer extract. The n-butanol layer extract is concentrated under reduced pressure and evaporated to dryness to obtain Paris polyphylla extract.

[0028] Preferably, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0029] (1) Add Paris polyphylla to a 65-75% (v / v) ethanol aqueous solution, heat and reflux to extract, filter, concentrate the filtrate under reduced pressure, add petroleum ether to the concentrate for extraction, extract the separated aqueous layer with ethyl acetate, then extract the separated aqueous layer with n-butanol to obtain the n-butanol layer extract, concentrate the n-butanol layer extract under reduced pressure and evaporate to dryness to obtain Paris polyphylla extract.

[0030] Preferably, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0031] (1) Add Paris polyphylla to a 65-75% (v / v) ethanol aqueous solution, heat and reflux for 1-2 hours, filter, concentrate the filtrate under reduced pressure, add petroleum ether to the concentrate for extraction, extract the separated aqueous layer with ethyl acetate, then extract the separated aqueous layer with n-butanol, and separate the n-butanol layer extract. The n-butanol layer extract is concentrated under reduced pressure and evaporated to dryness to obtain Paris polyphylla extract.

[0032] Preferably, in step (1), the volume ratio of the concentrate to the aqueous ethanol solution is 1:3-12, more preferably 1:3-10, even more preferably 1:4-8, more preferably 1:5-7, more preferably 1:5.5-6.5, and most preferably 1:6.

[0033] Preferably, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0034] (1) Add Paris polyphylla to a 70% (v / v) aqueous ethanol solution, heat and reflux to extract, and then add petroleum ether to the extract for extraction. The separated aqueous layer is extracted with ethyl acetate, and then the separated aqueous layer is extracted with n-butanol to obtain the n-butanol layer extract. The n-butanol layer extract is concentrated under reduced pressure and evaporated to dryness to obtain Paris polyphylla extract.

[0035] Preferably, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0036] (1) Take 200g of Paris polyphylla, add 1200mL of 70% (v / v) ethanol aqueous solution, heat and reflux for 1.5h, filter, concentrate the filtrate under reduced pressure to obtain 200mL of concentrate, add an equal volume of petroleum ether to the concentrate for extraction, extract the separated aqueous layer with an equal volume of ethyl acetate, and then extract the separated aqueous layer with an equal volume of n-butanol to obtain the n-butanol layer extract, concentrate the n-butanol layer extract under reduced pressure and evaporate to dryness to obtain Paris polyphylla extract.

[0037] Preferably, the Panax notoginseng extract is prepared by extraction with an aqueous ethanol solution.

[0038] Preferably, the Panax notoginseng extract includes an ethanol-water aqueous solution extract.

[0039] Preferably, the volume fraction of ethanol in the aqueous ethanol solution is 30-90%, more preferably 50-90%, even more preferably 60-80%, even more preferably 65-75%, even more preferably 68-72%, and most preferably 70%.

[0040] Preferably, the Panax notoginseng extract is prepared by the following method, the method comprising:

[0041] (a) Panax notoginseng was extracted with an aqueous ethanol solution to obtain Panax notoginseng extract.

[0042] Preferably, in step (a), the volume fraction of ethanol in the aqueous ethanol solution is 30-90%, more preferably 50-90%, more preferably 60-80%, more preferably 65-75%, more preferably 68-72%, and most preferably 70%.

[0043] Preferably, in step (a), the ethanol-water extraction is performed by heating and reflux extraction.

[0044] Preferably, in step (a), the extraction time of Panax notoginseng by the ethanol aqueous solution is 0.5-5h, more preferably 1-3h, more preferably 1-2h, more preferably 1.3-1.7h, and most preferably 1.5h.

[0045] Preferably, in step (a), the weight ratio of the Panax notoginseng raw material to the ethanol aqueous solution is 1:3-12, more preferably 1:3-10, even more preferably 1:4-8, more preferably 1:5-7, more preferably 1:5.5-6.5, and most preferably 1:6.

[0046] Preferably, the Panax notoginseng extract is prepared by the following method, the method comprising:

[0047] (a) Panax notoginseng is extracted with an aqueous ethanol solution to obtain an extract, which is then evaporated to dryness to obtain a Panax notoginseng extract.

[0048] Preferably, in step (a), Panax notoginseng is extracted with an aqueous ethanol solution and then filtered to obtain an extract.

[0049] Preferably, the evaporation is performed by vacuum concentration evaporation.

[0050] Preferably, the Panax notoginseng extract is prepared by the following method, the method comprising:

[0051] (a) Add Panax notoginseng to a 65-75% (v / v) aqueous ethanol solution, heat and reflux to extract, and then evaporate the extract to dryness to obtain Panax notoginseng extract.

[0052] Preferably, the Panax notoginseng extract is prepared by the following method, the method comprising:

[0053] (a) Add Panax notoginseng to a 70% (v / v) aqueous ethanol solution, heat and reflux to extract, and then evaporate the extract to dryness to obtain Panax notoginseng extract.

[0054] Preferably, the Panax notoginseng extract is prepared by the following method, the method comprising:

[0055] Take 200g of Panax notoginseng, add 1200mL of 70% (v / v) ethanol aqueous solution, heat and reflux for 1.5h, filter, and concentrate the filtrate under reduced pressure to dryness to obtain Panax notoginseng extract.

[0056] Preferably, the content of the Paris polyphylla extract is 0.001-99.9 wt%, more preferably 0.1-99 wt%, more preferably 1-99 wt%, more preferably 1-90 wt%, more preferably 10-90 wt%, more preferably 20-80 wt%, more preferably 30-70 wt%, more preferably 20-40 wt%, based on the weight of the composition.

[0057] Preferably, the content of the Panax notoginseng extract is 0.001-99.9 wt%, more preferably 0.1-99 wt%, more preferably 1-99 wt%, more preferably 1-90 wt%, more preferably 10-90 wt%, more preferably 20-80 wt%, more preferably 30-70 wt%, more preferably 20-40 wt%, based on the weight of the composition.

[0058] Preferably, the composition comprises an anti-aging composition.

[0059] Preferably, the composition is a pharmaceutical composition, a food composition, a health product composition, or a cosmetic composition.

[0060] Preferably, the composition further includes a pharmaceutically, food-grade, health product-grade, or cosmetically acceptable carrier.

[0061] Preferably, the dosage form of the composition is a solid dosage form, a semi-solid dosage form, or a liquid dosage form.

[0062] Preferably, the dosage form of the pharmaceutical composition, food composition, or health product composition is an oral preparation.

[0063] Preferably, the dosage form of the pharmaceutical composition or cosmetic composition is a topical preparation.

[0064] Preferably, the dosage form of the pharmaceutical composition or cosmetic composition is a cream, lotion, solution, spray, or patch.

[0065] Preferably, the composition is administered to a human being.

[0066] A second aspect of the present invention provides an active ingredient combination, the active ingredient combination comprising the following components:

[0067] (i) a first active ingredient, said first active ingredient comprising Paris polyphylla extract; and / or

[0068] (ii) A second active ingredient, wherein the second active ingredient includes Panax notoginseng extract.

[0069] Preferably, the Paris polyphylla extract is as described in the first aspect of the present invention.

[0070] Preferably, the Panax notoginseng extract is as described in the first aspect of the present invention.

[0071] Preferably, the combination of active ingredients includes a combination of anti-aging active ingredients.

[0072] Preferably, the weight ratio of the Paris polyphylla extract to the Panax notoginseng extract is 1:5-200, more preferably 1:5-100, even more preferably 1:10-90, even more preferably 1:10-80, even more preferably 1:10-70, even more preferably 1:20-60, even more preferably 1:25-55, even more preferably 1:30-50, even more preferably 1:35-45, even more preferably 1:38-42, and even more preferably 1:40.

[0073] Preferably, in the combination of active ingredients, at least one active ingredient is independent.

[0074] Preferably, in the combination of active ingredients, the first active ingredient and the second active ingredient are independent of each other.

[0075] A third aspect of the present invention provides a medicine box, food box, health product box, or cosmetic box, wherein the medicine box, food box, health product box, or cosmetic box comprises:

[0076] (A) A first formulation containing a first active ingredient, said first active ingredient comprising Paris polyphylla extract; and / or

[0077] (B) A second formulation containing a second active ingredient, said second active ingredient including Panax notoginseng extract.

[0078] Preferably, the Paris polyphylla extract is as described in the first aspect of the present invention.

[0079] Preferably, the Panax notoginseng extract is as described in the first aspect of the present invention.

[0080] Preferably, the medicine box, food box, health product box, or cosmetic box includes anti-aging medicine boxes, food boxes, health product boxes, or cosmetic boxes.

[0081] Preferably, the weight ratio of the Paris polyphylla extract to the Panax notoginseng extract is 1:5-200, more preferably 1:5-100, even more preferably 1:10-90, even more preferably 1:10-80, even more preferably 1:10-70, even more preferably 1:20-60, even more preferably 1:25-55, even more preferably 1:30-50, even more preferably 1:35-45, even more preferably 1:38-42, and even more preferably 1:40.

[0082] Preferably, the first and second formulations are independent formulations.

[0083] Preferably, the first and second formulations are combined formulations.

[0084] Preferably, the medicine box, food box, health product box, or cosmetic box also includes an instruction manual.

[0085] Preferably, the instructions for use specify that the first preparation and the second preparation are used in combination for anti-aging purposes.

[0086] The fourth aspect of the present invention provides the use of a composition as described in the first aspect of the present invention, an active ingredient combination as described in the second aspect of the present invention, or a medicine box, food box, health product box, or cosmetic box as described in the third aspect of the present invention, for the preparation of a drug, food, health product, or cosmetic, wherein the drug, food, health product, or cosmetic is used for anti-aging.

[0087] Preferably, the anti-aging includes prevention and / or treatment of aging.

[0088] Preferably, the aging includes skin aging.

[0089] Preferably, the aging process includes human aging.

[0090] Preferably, the anti-aging target includes humans.

[0091] Preferably, the skin includes human skin.

[0092] Preferably, the aging includes aging caused by light radiation.

[0093] Preferably, the aging includes aging caused by ultraviolet radiation.

[0094] Preferably, the ultraviolet light includes UVA ultraviolet light.

[0095] Preferably, the aging includes aging caused by a decrease in type III collagen.

[0096] Preferably, the anti-aging method includes increasing type III collagen levels to combat aging.

[0097] Preferably, the level includes the content level.

[0098] Preferably, the type III collagen includes type III collagen in skin cells.

[0099] Preferably, the type III collagen includes type III collagen from skin fibroblasts.

[0100] Preferably, the skin fibroblasts include human skin fibroblasts HFF-1.

[0101] Preferably, the drug, food, health product, or cosmetic is applied to humans.

[0102] Preferably, the dosage form of the drug, food, health product or cosmetic is a solid dosage form, a semi-solid dosage form or a liquid dosage form.

[0103] Preferably, the dosage form of the drug, food, or health product is an oral preparation.

[0104] Preferably, the dosage form of the drug or cosmetic is a topical preparation.

[0105] Preferably, the dosage form of the drug or cosmetic is a cream, lotion, solution, spray, or patch.

[0106] The fifth aspect of this invention provides a method for increasing the content of type III collagen in skin fibroblasts, the method comprising the steps of:

[0107] Contacting skin fibroblasts with a composition as described in the first aspect of the invention or a combination of active ingredients as described in the second aspect of the invention increases the content of type III collagen in skin fibroblasts.

[0108] Preferably, the skin fibroblasts include human skin fibroblasts.

[0109] Preferably, the skin fibroblasts include human skin fibroblasts HFF-1.

[0110] Preferably, the skin fibroblasts include skin fibroblasts exposed to ultraviolet radiation.

[0111] Preferably, the ultraviolet light includes UVA ultraviolet light.

[0112] Preferably, the method includes non-therapeutic and non-diagnostic methods.

[0113] Preferably, the method includes an in vitro method.

[0114] Preferably, the contact includes external contact.

[0115] Preferably, the contact includes contact in an in vitro culture medium.

[0116] The sixth aspect of the present invention provides a method for anti-aging, the method comprising applying to a desired object a composition as described in the first aspect of the present invention, a combination of active ingredients as described in the second aspect of the present invention, or a medicine box, food box, health product box, or cosmetic box as described in the third aspect of the present invention, thereby achieving anti-aging.

[0117] Preferably, the object includes a person.

[0118] Preferably, the anti-aging includes prevention and / or treatment of aging.

[0119] Preferably, the aging includes skin aging.

[0120] Preferably, the aging process includes human aging.

[0121] Preferably, the skin includes human skin.

[0122] Preferably, the aging includes aging caused by light radiation.

[0123] Preferably, the aging includes aging caused by ultraviolet radiation.

[0124] Preferably, the ultraviolet light includes UVA ultraviolet light.

[0125] Preferably, the aging includes aging caused by a decrease in type III collagen.

[0126] Preferably, the anti-aging method includes increasing type III collagen levels to combat aging.

[0127] Preferably, the level includes the content level.

[0128] Preferably, the type III collagen includes type III collagen in skin cells.

[0129] Preferably, the type III collagen includes type III collagen from skin fibroblasts.

[0130] Preferably, the skin fibroblasts include human skin fibroblasts HFF-1.

[0131] It should be understood that, within the scope of this invention, the above-described technical features of this invention and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Attached Figure Description

[0132] Figure 1 The value of COL-3 (type III collagen) in the cell lysis supernatant after treatment in each group is given. p represents whether there is a significant difference compared with the model group. "*" indicates p < 0.05, indicating a significant difference; "**" indicates p < 0.01, indicating an extremely significant difference. Detailed Implementation

[0133] This invention develops a Paris polyphylla extract and a Panax notoginseng extract, which have excellent anti-aging effects. Furthermore, experimental studies of this invention show that specific amounts of Paris polyphylla extract and Panax notoginseng extract have excellent synergistic effects in anti-aging.

[0134] the term

[0135] As used herein, the terms “comprising,” “including,” and “containing” are used interchangeably and include not only open-ended definitions but also semi-closed and closed definitions. The terms include “consisting of” and “substantially consisting of”.

[0136] In this invention, the term "Paris fargesii Franch." refers to the dried rhizome of the herb *Paris fargesii* Franch.

[0137] In this invention, the term "Sanqi" refers to the dried root of Panax notoginseng (Burk.) FHChen, a plant belonging to the Araliaceae family.

[0138] In this invention, the term "aloe" refers to the product being the concentrated and dried juice of the leaves of Aloe barbadensis Miller, a plant of the Liliaceae family.

[0139] As used herein, the term “70% (v / v) aqueous ethanol solution” refers to an aqueous solution of ethanol with a volume fraction of 70%, for example, “70% (v / v) aqueous ethanol solution is prepared by mixing 70 mL of anhydrous ethanol and 30 mL of water, and so on.”

[0140] As used in this article, the term "COL-3" refers to type III collagen, or Collagen Type III Protein in English.

[0141] As used in this article, the term "DMEM medium" refers to Dulbecco's Modified Eagle Medium.

[0142] As used in this article, the term "ELISA" refers to enzyme-linked immunosorbent assay.

[0143] In this invention, the term "prevention" means a method of preventing the onset of a disease and / or its accompanying symptoms or protecting a subject from acquiring a disease.

[0144] In this invention, the term "treatment" includes delaying and stopping the progression of a disease, or eliminating the disease, without requiring 100% inhibition, eradication, and reversal.

[0145] Paris polyphylla extract

[0146] This invention provides a Paris polyphylla extract, which has excellent anti-aging effects.

[0147] In a preferred embodiment of the present invention, the Paris polyphylla extract is prepared by the following method, the method comprising:

[0148] (1) Extract Paris polyphylla with an aqueous ethanol solution to obtain an extract. The extract is then extracted with petroleum ether, and the separated aqueous layer is extracted with ethyl acetate. The separated aqueous layer is then extracted with n-butanol to obtain an n-butanol layer extract. The n-butanol layer extract is then evaporated to dryness to obtain Paris polyphylla extract.

[0149] Specifically, the Paris polyphylla extract described in this invention is as described in the first aspect of this invention above.

[0150] Panax notoginseng extract

[0151] This invention provides a Panax notoginseng extract, which has excellent anti-aging effects.

[0152] In a preferred embodiment of the present invention, the Panax notoginseng extract is prepared by the following method, the method comprising:

[0153] (a) Panax notoginseng was extracted with an aqueous ethanol solution to obtain Panax notoginseng extract.

[0154] Specifically, the Panax notoginseng extract described in this invention is as described in the first aspect of this invention above.

[0155] use

[0156] The Paris polyphylla extract and Panax notoginseng extract described in this invention have excellent anti-aging effects, and the Paris polyphylla extract and Panax notoginseng extract described in this invention have excellent synergistic effects in anti-aging.

[0157] In a preferred embodiment of the invention, the anti-aging includes preventing and / or treating aging.

[0158] The aging process described in this invention is preferably skin aging, such as human skin aging.

[0159] In a preferred embodiment of the invention, the aging includes aging caused by light radiation (such as ultraviolet radiation).

[0160] In a preferred embodiment of the invention, the anti-aging process includes increasing type III collagen levels to combat aging.

[0161] In a preferred embodiment of the present invention, the aging includes aging caused by a decrease in type III collagen.

[0162] Preferably, the type III collagen includes type III collagen in skin cells.

[0163] Preferably, the type III collagen includes type III collagen from skin fibroblasts.

[0164] Preferably, the skin fibroblasts include human skin fibroblasts HFF-1.

[0165] Composition

[0166] The present invention also provides a composition, preferably a pharmaceutical composition, a food composition, a health product composition, or a cosmetic composition. The composition of the present invention further includes a pharmaceutically, food-, health product-, or cosmetically acceptable carrier.

[0167] As used herein, the term "pharmaceutical, food, health product or cosmetic acceptable carrier" refers to one or more compatible solid, semi-solid, liquid or gel fillers that are suitable for human or animal use and have sufficient purity and sufficiently low toxicity.

[0168] It should be understood that the carrier described in this invention is not particularly limited and can be any material commonly used in the art, prepared by conventional methods, or purchased from the market. Acceptable examples of carriers include cellulose and its derivatives (such as methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, etc.), polyols (such as propylene glycol, glycerin, sorbitol, etc.), emulsifiers (such as Tween), wetting agents (such as sodium dodecyl sulfate), buffers, chelating agents, thickeners, pH adjusters, transdermal absorption promoters, colorants, flavoring agents, stabilizers, antioxidants, preservatives, antibacterial agents, pyrogen-free water, etc.

[0169] In a preferred embodiment of the present invention, the composition of the present invention comprises Paris polyphylla extract and Panax notoginseng extract.

[0170] In a preferred embodiment of the present invention, the weight ratio of the Paris polyphylla extract to the Panax notoginseng extract is 1:5-200, more preferably 1:5-100, more preferably 1:10-90, more preferably 1:10-80, more preferably 1:10-70, more preferably 1:20-60, more preferably 1:25-55, more preferably 1:30-50, more preferably 1:35-45, more preferably 1:38-42, and more preferably 1:40.

[0171] In this invention, the dosage form of the composition includes (but is not limited to) solid dosage forms, semi-solid dosage forms, or liquid dosage forms.

[0172] Pharmaceutical formulations should be matched with the route of administration, which involves administering a therapeutically effective amount of the drug to the intended recipient (e.g., a human or non-human mammal). As used herein, the term "therapeutically effective amount" refers to an amount that is functionally or activityily produced in humans and / or animals and is acceptable to them. Those skilled in the art will understand that the "therapeutically effective amount" can vary depending on the form of the pharmaceutical formulation, the route of administration, the excipients used, the severity of the disease, and whether it is used in combination with other drugs, all of which are within the scope of the skill of a skilled physician.

[0173] The main technical effects achieved by this invention include:

[0174] This invention develops a Paris polyphylla extract and a Panax notoginseng extract, which have excellent anti-aging effects (such as anti-skin aging) and exhibit excellent synergistic effects in anti-aging.

[0175] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that the following specific embodiments are based on the present technical solution and provide detailed implementation methods and specific operation processes, but the scope of protection of the present invention is not limited to these embodiments.

[0176] Example

[0177] COL-3 refers to type III collagen, or Collagen Type III Protein in English.

[0178] Example 1

[0179] This embodiment examines the effects of different Chinese herbal extracts and their combinations on anti-aging.

[0180] 1. Preparation of different Chinese herbal extracts

[0181] 1.1 Preparation of Paris polyphylla extract

[0182] (1) Take 200g of crushed Paris polyphylla, add 1200mL of 70% (v / v) ethanol aqueous solution, heat and reflux for 1.5h, filter, concentrate the filtrate under reduced pressure to obtain 200mL concentrate, add an equal volume of petroleum ether to the concentrate for extraction, extract the separated aqueous layer with an equal volume of ethyl acetate, then extract the separated aqueous layer with an equal volume of n-butanol, separate the n-butanol layer extract, concentrate the n-butanol layer extract under reduced pressure and evaporate to dryness to obtain Paris polyphylla extract.

[0183] 1.2 Preparation of Panax notoginseng extract

[0184] Take 200g of crushed Panax notoginseng, add 1200mL of 70% (v / v) ethanol aqueous solution, heat and reflux for 1.5h, filter, and concentrate the filtrate under reduced pressure to dryness to obtain Panax notoginseng extract.

[0185] 1.3 Preparation of Aloe Vera Extract

[0186] Take 200g of crushed aloe vera, add 1200mL of water, stir and extract at 70℃ for 3h, filter, centrifuge the filtrate at 8000r / min for 15min, collect the supernatant and concentrate under reduced pressure to obtain 200mL of concentrate. Add Sevag reagent (Sevag reagent is a mixture of chloroform and n-butanol, where the volume ratio of chloroform to n-butanol is 5:1) at a volume ratio of 4:1 and shake thoroughly for 20min (i.e., remove protein by Sevag method). Centrifuge at 8000r / min for 5min to separate the supernatant. Add 4 times the volume of 80% (v / v) ethanol aqueous solution to the supernatant while stirring. Let stand at 4℃ for 12h, filter to obtain precipitate, and dry the precipitate to obtain aloe vera extract.

[0187] 2. Investigation on the anti-aging effects of different Chinese herbal extracts and their combinations

[0188] 2.1 Experimental Methods and Results

[0189] (1) A blank control group, a model group, experimental groups A, B, C, D, E, F, G, and H were set up. Each group used 2 × 10⁻⁶ human skin fibroblasts (HFF-1, from the Peking Union Medical College Cell Bank) in the logarithmic growth phase. 6 Cells were seeded at a density of cells / mL onto multi-well cell culture plates, with 1 mL of cell suspension added to each well. After incubation overnight at 37°C and 5% CO2, the supernatant was discarded. Then, 1 mL of the same volume of the following drug was added to each well for treatment:

[0190] Control group: DMEM medium;

[0191] Model group: DMEM medium;

[0192] Experimental group A: DMEM medium dispersion of Paris polyphylla extract, wherein the concentration of Paris polyphylla extract was 1.25 μg / mL;

[0193] Experimental group B: DMEM medium dispersion of Panax notoginseng extract, wherein the concentration of Panax notoginseng extract is 0.5 mg / mL;

[0194] Experimental group C: DMEM medium dispersion of aloe vera extract, wherein the concentration of aloe vera extract was 2.5 mg / mL;

[0195] Experimental group D: DMEM medium dispersion of Paris polyphylla extract and Panax notoginseng extract, wherein the concentration of Paris polyphylla extract was 1.25 μg / mL and the concentration of Panax notoginseng extract was 0.5 mg / mL;

[0196] Experimental group E: DMEM medium dispersions of Paris polyphylla extract and Panax notoginseng extract, wherein the concentration of Paris polyphylla extract was 1.25 μg / mL and the concentration of Panax notoginseng extract was 0.05 mg / mL;

[0197] Experimental group F: DMEM medium dispersions of Paris polyphylla extract, Panax notoginseng extract and Aloe vera extract, wherein the concentration of Paris polyphylla extract was 1.25 μg / mL, the concentration of Panax notoginseng extract was 0.5 mg / mL and the concentration of Aloe vera extract was 2.5 mg / mL.

[0198] Experimental group G: DMEM medium dispersions of Paris polyphylla extract, Panax notoginseng extract and Aloe vera extract, wherein the concentration of Paris polyphylla extract was 1.25 μg / mL, the concentration of Panax notoginseng extract was 0.05 mg / mL and the concentration of Aloe vera extract was 2.5 mg / mL.

[0199] Experimental group H: DMEM medium dispersions of Paris polyphylla extract, Panax notoginseng extract and Aloe vera extract, wherein the concentration of Paris polyphylla extract was 1.25 μg / mL, the concentration of Panax notoginseng extract was 0.05 mg / mL and the concentration of Aloe vera extract was 1.25 mg / mL.

[0200] Each group was repeated three times. After drug administration, each group was incubated at 37℃ and 5% CO2 for 6 hours. Then, except for the control group, all other groups were subjected to the same UVA ultraviolet stimulation (9 J / cm²). 2 After UV stimulation, each group was cultured for another 24 hours. The culture medium was removed from each well, and the cells were washed once with PBS 7.4 buffer. Then, 400 μL of cell lysis buffer (prepared at a RIPA:PMSF ratio of 100:1) was added to each well. The cells were pipetted several times to minimize air bubbles. The cells were then centrifuged at 10000 rpm at 4°C for 5 minutes. The supernatant was collected, and the COL-3 (type III collagen) content in the cell lysis supernatant was detected using an ELISA kit (Cloud-Clone Crop). The COL-3 (type III collagen) content in the cell lysis supernatant of each group is shown below. Figure 1 As shown in Table 1.

[0201] Table 1. COL-3 (Type III collagen) content in cell lysate supernatant after treatment in each group (M±SD)

[0202]

[0203] Note: Except for the control group, all other groups were stimulated with the same UVA ultraviolet light (9J / cm²). 2 ).

[0204] from Figure 1As shown in Table 1, compared with the model group, the Paris polyphylla extract, Panax notoginseng extract, and Aloe vera extract prepared in Example 1 can effectively increase the content of type III collagen in skin fibroblasts, thus exhibiting excellent anti-skin aging effects. Specifically, compared with the individual use of Paris polyphylla extract and Panax notoginseng extract in experimental groups A and B to increase the content of type III collagen in skin fibroblasts, the combined use of specific amounts of Paris polyphylla extract and Panax notoginseng extract in experimental group E has a synergistic effect in increasing the content of type III collagen in skin fibroblasts. Therefore, the combined use of specific amounts of Paris polyphylla extract and Panax notoginseng extract in experimental group E has a synergistic effect in anti-skin aging, thereby significantly improving the anti-aging effect.

[0205] The above description is merely a preferred embodiment of this application and is not intended to limit this application. Various modifications and variations can be made to this application by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this application should be included within the protection scope of this application.

Claims

1. An anti-aging composition characterized in that, The anti-aging composition is made of a Paris extract and a Panax notoginseng extract; The Paris extract is prepared by the following method, which comprises: (1) extracting Paris with an ethanol aqueous solution to obtain an extract, extracting the separated water layer with ethyl acetate, then extracting the separated water layer with n-butanol to obtain an n-butanol layer extract, and evaporating the n-butanol layer extract to obtain the Paris extract; The Panax notoginseng extract is prepared by the following method, which comprises: (a) extracting Panax notoginseng with an ethanol aqueous solution to obtain a Panax notoginseng extract, wherein the Panax notoginseng extract is a dry extract; In step (1), the volume fraction of ethanol in the ethanol aqueous solution is 65-75%; In step (a), the volume fraction of ethanol in the ethanol aqueous solution is 65-75%; The weight ratio of the Paris extract to the Panax notoginseng extract is 1:38-42.

2. The anti-aging composition according to claim 1, wherein The weight ratio of the Paris extract to the Panax notoginseng extract is 1:38-42.

3. The anti-aging composition according to claim 1, wherein The weight ratio of the Paris extract to the Panax notoginseng extract is 1:

40.

4. The anti-aging composition according to claim 1, wherein In the ethanol aqueous solution, the volume fraction of ethanol is 68-72%; and In step (a), the volume fraction of ethanol in the ethanol aqueous solution is 68-72%.

5. The anti-aging composition according to claim 1, wherein In the ethanol aqueous solution, the volume fraction of ethanol is 70%; and In step (a), the volume fraction of ethanol in the ethanol aqueous solution is 70%.

6. The anti-aging composition according to claim 1, wherein The Paris extract is prepared by the following method, which comprises: (1) adding Paris to a 65-75%(v / v) ethanol aqueous solution, heating and refluxing to extract to obtain an extract, adding petroleum ether to the extract to extract, extracting the separated water layer with ethyl acetate, then extracting the separated water layer with n-butanol to obtain an n-butanol layer extract, and evaporating the n-butanol layer extract to obtain the Paris extract; The Panax notoginseng extract is prepared by the following method, which comprises: (a) adding Panax notoginseng to a 65-75%(v / v) ethanol aqueous solution, heating and refluxing to extract to obtain an extract, and evaporating the extract to obtain the Panax notoginseng extract.

7. The anti-aging composition according to claim 1, wherein The anti-aging composition is a pharmaceutical composition or a cosmetic composition.

8. The anti-aging composition according to claim 1, wherein The anti-aging composition further comprises a pharmaceutically or cosmetically acceptable carrier.

9. The anti-aging composition according to claim 1, wherein The dosage form of the anti-aging composition is a solid preparation, a semi-solid preparation or a liquid preparation.

10. Use of an anti-aging composition according to claim 1, characterized in that, The anti-aging composition is used for preparing a medicine or a cosmetic.

11. Use according to claim 10, characterized in that, The aging includes human skin aging.

12. The use according to claim 10, characterized in that, The aging includes ultraviolet radiation-induced aging.

13. The use according to claim 10, characterized in that, The dosage form of the medicine or the cosmetic is a solid preparation, a semi-solid preparation or a liquid preparation.

Images